Use of Natriuretic Peptides in the Emergency Department and the ICU

  • T. Reichlin
  • M. Noveanu
  • C. Mueller


The clinical importance of a specific disease marker is related to the overall importance of the disease or biological signal it quantifies, the availability of alternative methods to reliably diagnose the disease and quantify disease severity, and, of course, the performance of the marker. Natriuretic peptides, as quantitative markers of cardiac stress and heart failure, owe their clinical importance to the fact that heart failure is a major public health problem, the uncertainty in the clinical diagnosis and management of heart failure, and to their excellent diagnostic and prognostic utility [1, 2, 3, 4, 5].


Natriuretic Peptide Brain Natriuretic Peptide Acute Decompensated Heart Failure Cardiogenic Pulmonary Edema Natriuretic Peptide Level 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Nieminen MS, Böhm M, Cowie MR, et al (2005) Executive summary of the guidelines on the diagnosis and treatment of acute heart failure. Eur Heart J 26: 384–416CrossRefPubMedGoogle Scholar
  2. 2.
    Cowie MR, Struthers AD, Wood DA, et al (1997) Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 350: 1349–1353CrossRefPubMedGoogle Scholar
  3. 3.
    Mueller C, Breidthardt T, Laule-Kilian K, Christ M, Perruchoud AP (2007) The integration of BNP and NT-proBNP into clinical medicine. Swiss Med Wkly 137: 4–12PubMedGoogle Scholar
  4. 4.
    Maisel AS, Krishnaswamy P, Nowak RM, et al (2002) Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347: 161–167CrossRefPubMedGoogle Scholar
  5. 5.
    McCullough PA, Nowak RM, McCord J, et al (2002) B-type natriuretic peptide and clinical judgement in emergency diagnosis of heart failure. Analysis from Breathing Not Properly (BNP) Multinational Study. Circulation 106: 416–422CrossRefPubMedGoogle Scholar
  6. 6.
    Gegenhuber A, Struck J, Poelz W, et al (2006) Midregional pro-A-type natriuretic peptide measurements for diagnosis of acute destabilized heart failure in short-of-breath patients: comparison with B-type natriuretic peptide (BNP) and amino-terminal proBNP. Clin Chem 52: 827–831CrossRefPubMedGoogle Scholar
  7. 7.
    Gegenhuber A, Struck J, Dieplinger B, et al (2007) Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure. J Card Fail 13: 42–49CrossRefPubMedGoogle Scholar
  8. 8.
    Potocki M, Breidthardt T, Reichlin T, et al (2008) Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in the diagnosis of heart failure. Eur Heart J 29:180a (abst)Google Scholar
  9. 9.
    Mukoyama M, Nakao K, Hosoda K, et al (1991) Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 87: 1402–1412CrossRefPubMedGoogle Scholar
  10. 10.
    Yasue H, Yoshimura M, Sumida H, et al (1994) Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 90: 195–203PubMedGoogle Scholar
  11. 11.
    Davis M, Espiner E, Richards G, et al (1994) Plasma brain natriuretic peptide in assessment of acute dyspnea. Lancet 343: 440–444CrossRefPubMedGoogle Scholar
  12. 12.
    McDonagh TA, Robb SD, Murdoch DR, et al (1998) Biochemical detection of left-ventricular systolic dysfunction. Lancet 351: 9–13CrossRefPubMedGoogle Scholar
  13. 13.
    Iwanaga Y, Nishi I, Furuichi S, et al (2006) B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure. Comparison between systolic and diastolic heart failure. J Am Coll Cardiol 47: 742–748CrossRefPubMedGoogle Scholar
  14. 14.
    Watanabe S, Shite J, Takaoka H, et al (2006) myocardial stiffness is an important determinant of the plasma brain natriuretic peptide concentration in patients with both diastolic and systolic heart failure. Eur Heart J 27: 832–838CrossRefPubMedGoogle Scholar
  15. 15.
    Troughton RW, Prior DL, Pereira JJ, et al (2004) Plasma B-type natriuretic peptide levels in systolic heart failure. Importance of left ventricular diastolic function and right ventricular systolic function. J Am Coll Cardiol 43: 416–422CrossRefPubMedGoogle Scholar
  16. 16.
    Lainchbury JG, Campbell E, Frampton CM, et al (2003) Brain natriuretic peptide and N-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol 42: 728–735CrossRefPubMedGoogle Scholar
  17. 17.
    Svendstrup Nielsen L, Svanegaard J, Klitgaard NA, Egeblad H (2004) N-terminal pro-brain natriuretic peptide for discriminating between cardiac and non-cardiac dyspnoea. Eur J Heart Fail 6: 63–70CrossRefGoogle Scholar
  18. 18.
    Dao Q, Krishnaswamy P, Kazanegra R, et al (2001) Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol 37: 379–385CrossRefPubMedGoogle Scholar
  19. 19.
    Januzzi JL, Camargo CA, Anwaruddin S, et al (2005) The N-terminal pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 95: 948–954CrossRefPubMedGoogle Scholar
  20. 20.
    Januzzi JL, van Rimmenade R, Lainchbury J, et al (2006) NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients. The International Collaborative of NT-proBNP Study. Eur Heart J 27: 330–337CrossRefPubMedGoogle Scholar
  21. 21.
    Wright SP, Doughty RN, Pearl A, et al (2003) Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care. A randomized, controlled trial. J Am Coll Cardiol 42: 1793–1800CrossRefPubMedGoogle Scholar
  22. 22.
    Zaphiriou A, Robb S, Murray-Thomas T, et al (2005) The diagnostic accuracy of plasma BNP and NTproBNP in patients referred from primary care with suspected heart failure: results of the UK natriuretic peptide study. Eur J Heart Fail 7: 537–541CrossRefPubMedGoogle Scholar
  23. 23.
    Ray P, Arthaud M, Birolleau S, et al (2005) Comparison of brain natriuretic peptide and probrain natriuretic peptide in the diagnosis of cardiogenic pulmonary edema in patients aged 65 and older. J Am Geriatr Soc 53: 643–648CrossRefPubMedGoogle Scholar
  24. 24.
    Mueller T, Gegenhuber A, Poelz W, Haltmayer M (2005) Diagnostic accuracy of b-type natriuretic peptide and amino terminal proBNP in the emergency diagnosis of heart failure. Heart 91: 606–612CrossRefPubMedGoogle Scholar
  25. 25.
    Fonarow GC, Peacock WF, Phillips CO, et al (2007) Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure ADHERE Scientific Advisory Committee and Investigators. J Am Coll Cardiol 49: 1943–1950CrossRefPubMedGoogle Scholar
  26. 26.
    Januzzi JL, Sakhuja R, O’Donoghue M, et al (2006) Utility of amino-terminal pro-brain natriuretic peptide testing for the prediction of 1-year mortality in patients with dyspnea treated in the emergency department. Arch Intern Med 166: 315–320CrossRefPubMedGoogle Scholar
  27. 27.
    Christ M, Laule-Kilian K, Hochholzer W, et al (2006) Gender-specific risk stratification using B-type natriuretic peptide levels in patients with acute dyspnea: Insights from the BASEL study. J Am Coll Cardiol 48: 1808–1812CrossRefPubMedGoogle Scholar
  28. 28.
    Christ M, Thuerlimann A, Laule K, et al (2007) Long-term prognostic value of B-type natriuretic peptide level in cardiac and non-cardiac causes of acute dyspnea. Eur J Clin Invest 37: 834–841CrossRefPubMedGoogle Scholar
  29. 29.
    Maisel AS, Clopton P, Krishnaswamy P, et al (2004) Impact of age, race, and sex on the ability of B-type natriuretic peptide to aid in the emergency diagnosis of heart failure: results from Breathing Not Properly (BNP) Multinational Study. Am Heart J 147: 1078–1084CrossRefPubMedGoogle Scholar
  30. 30.
    Mueller C, Laule-Kilian K, Scholer A, et al (2004) Use of B-type natriuretic peptide for the management of women with dyspnea. Am J Cardiol 94: 1510–1514CrossRefPubMedGoogle Scholar
  31. 31.
    McCullough PA, Duc P, Omland T, et al (2003) B-type natriuretic peptide and renal function in the diagnosis of heart failure: an Analysis from the breathing not properly multinational study. Am J Kidney Dis 41: 571–575CrossRefPubMedGoogle Scholar
  32. 32.
    Mueller C, Laule Kilian K, Scholer A, et al (2005) B-type natriuretic peptide for acute dyspnea in patients with kidney disease: insights from a randomized comparison. Kidney Int 67: 278–284.CrossRefPubMedGoogle Scholar
  33. 33.
    Wang TJ, Larson MG, Levy D, et al (2004) Impact of obesity on plasma natriuretic peptide levels. Circulation 109: 594–600CrossRefPubMedGoogle Scholar
  34. 34.
    McCord J, Mundy BJ, Hudson MP, et al (2004) Relationship between obesity and B-type natriuretic peptide levels. Arch Intern Med 164: 2247–2252CrossRefPubMedGoogle Scholar
  35. 35.
    Krauser DG, Llyod-Jones DM, Chae CU, et al (2005) Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: a proBNP Investigation of dyspnea in the emergency department (PRIDE) substudy. Am Heart J 149: 744–750CrossRefPubMedGoogle Scholar
  36. 36.
    Mueller C, Scholer A, Laule-Kilian K, et al (2004) Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 350: 647–654CrossRefPubMedGoogle Scholar
  37. 37.
    Moe GW, Howlett J, Januzzi JL, et al (2007) N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study. Circulation 115: 3103–3110CrossRefPubMedGoogle Scholar
  38. 38.
    Mueller C, Laule-Kilian K, Schindler C, et al (2006) Cost-effectiveness of B-type natriuretic peptide testing in patients with acute dyspnea. Arch Intern Med 166: 1081–1087CrossRefPubMedGoogle Scholar
  39. 39.
    Breidthardt T, Laule K, Strohmeyer AH, et al (2007) Medical and economic long-term effects of B-type natriuretic peptide testing in patients with acute dyspnea. Clin Chem 53: 1415–1422CrossRefPubMedGoogle Scholar
  40. 40.
    Maisel AS, Peacock WF, McMullin N, Jessie R, Fonarow GC, Wynne J, Mills RM (2008) Timing of immunoreactive B-type natriuretic peptide levels and treatment delay in acute decompensated heart failure: an ADHERE (Acute Decompensated Heart Failure National Registry) analysis. J Am Coll Cardiol 52: 534–540CrossRefPubMedGoogle Scholar
  41. 41.
    Mueller C (2007) The use of B-type natriuretic peptides in the intensive care unit. Crit Care Med 35: 2438–2439CrossRefPubMedGoogle Scholar
  42. 42.
    Jefic D, Lee JW, Jefic D, et al (2005) Utility of B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide in evaluation of respiratory failure in critically ill patients. Chest 128: 288–295CrossRefPubMedGoogle Scholar
  43. 43.
    Bal L, Thierry S, Brocas E, et al (2006) B-type natriuretic peptide (BNP) and N-terminalproBNP for heart failure diagnosis in shock or acute respiratory distress. Acta Anaesthesiol Scand 50: 340–347CrossRefPubMedGoogle Scholar
  44. 44.
    Forfia PR, Watkins SP, Rame JE, et al (2005) Relationship between B-type natriuretic peptides and pulmonary capillary wedge pressure in the intensive care unit. J Am Coll Cardiol 45: 1667–1671CrossRefPubMedGoogle Scholar
  45. 45.
    Karmpaliotis D, Kirtane AJ, Ruisi CP, et al (2007) Diagnostic and prognostic utility of brain natriuretic Peptide in subjects admitted to the ICU with hypoxic respiratory failure due to noncardiogenic and cardiogenic pulmonary edema. Chest 131: 964–971CrossRefPubMedGoogle Scholar
  46. 46.
    Maisel AS, Mueller C, Adams K, et al (2008) State of the art: Using natriuretic peptide levels in clinical practice. Eur J Heart Fail 10: 824–839CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2009

Authors and Affiliations

  • T. Reichlin
    • 1
  • M. Noveanu
    • 1
  • C. Mueller
    • 1
  1. 1.Department of MedicineUniversity HospitalBaselSwitzerland

Personalised recommendations